Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients
Conclusion
PMI might be a predictive marker of tolerance to treatment and TTF in HCC patients receiving sorafenib treatment.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
More News: Cancer & Oncology | Carcinoma | CT Scan | Gastroenterology | Hepatocellular Carcinoma | Liver Cancer | Statistics | Study | Women